Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. RGEN.NASDAQ

Repligen Corporation (RGEN NASDAQ) stock market data APIs

$134.91 -5.88(-4.2%) as of July 26, 2024
Price chart is built with Anychart

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation Financial Data Overview

140.79
134.91
-
143.775
134.35
110.45-211.13
7 396 M
509.0769
55 876 K
607 M
0.953
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'RGEN',
Type: 'Common Stock',
Name: 'Repligen Corporation',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000BS48J3',
ISIN: NULL,
CUSIP: NULL,
CIK: '730272',
EmployerIdNumber: '04-2729386',
FiscalYearEnd: 'December',
IPODate: '1990-03-26',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Medical Instruments & Supplies',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Repligen Corporation Fundamental Data is available in our Financial Data APIs

  • Net Revenue 607 M
  • EBITDA 95 371 K
  • Earnings Per Share 0.26
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Repligen Corporation Earnings via APIs

  • Latest Release 2024-07-30
  • EPS/Forecast 0.33

Get Repligen Corporation End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Repligen Corporation latest news via APIs

Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

The market expects Exact Sciences (EXAS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outloo...

Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for

Wall Street expects a year-over-year decline in earnings on lower revenues when Repligen (RGEN) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important ...
Do you have any questions?
support@eodhistoricaldata.com